top of page

The Company

Novapep is an Australian-US biotech company which has developed its Biparetide agonist peptide structure, which mimics the mechanisms of action of Activated Protein C ('APC'). APC and Biparetide activate PAR1 and PAR3 cell receptors, which produces anti-inflammatory and cytoprotective cell signalling.  The Company’s primary target diseases inflammatory bowel disease ('IBD') and sepsis.

 

Novapep’s co-founders, Professor John Griffin at the Scripps Research Institute in San Diego and Professor Chris Jackson at the University of Sydney, have conducted over 15 years of ground-breaking R&D in APC.  Professor Griffin invented the PAR1 agonist peptide and subsequently Biparetide - the PAR1/PAR3 conjugated agonist peptide.

 

Novapep has licensed the Biparetide patents from the Scripps, which provide IP protection to 2039 and Novapep is currently pursuing formulation patents

The competitive advantages of Biparetide include:

  • Biparetide far cheaper to manufacture than APC, is stable and is well suited to systemic and oral delivery methods.

 

  • Current treatments for these disease have significant side effects and/or are far more expensive to manufacture                than biparetide formulations.

​​

  • Biparetide exerts multiple protective mechanisms of action in target diseases.

​​

  • Successful translation of Biparetide formulations will make them first in class drugs for Novapep's target indications.

bottom of page